Paul Capital stakes $100 million to fund late-stage clinical trial firm
This article was originally published in Scrip
Executive Summary
Paul Capital Healthcare, part of the Paul Capital investment group, has committed up to $100 million in initial funding to the recently formed clinical trials firm Phase III Development Company (P3D), which has agreed a development deal with an unnamed major pharmaceutical company.